Despite keen interest in BAFF-R inhibition, rheumatologists favor BMS’ Sotyktu (deucravacitinib) as the leading therapy in development for Sjögren’s.EXTON, PA, Oct. 02, 2024 (GLOBE NEWSWIRE) -- ...
"Athletes may need some time off before returning, but others may miss little to no time if the sprain is mild and the shoulder exhibits full range of motion," Haines noted. Recovery times can range ...